New immunotherapy drug combinations are helping patients with advanced kidney cancer live from 10-15 years longer than ever ...

Higher BMI post-diagnosis is linked to better survival outcomes in localized RCC patients, while significant weight loss predicts poorer prognosis. Monitoring BMI changes during survivorship could ...

(Reuters) - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone ...

High survival rates in localized kidney cancer contrast with patients' uncertainty about their prognosis, affecting their quality of life. The distinction between feeling "cured" and "consumed" by ...

A method to address discrepancies between predicted biological age and actual chronological age has been validated as a biomarker in predicting OS.

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

Dr Huw Morgan, Cardiff University’s European Cancer Stem Cell Research Institute, was awarded the three-year Advanced ...